期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨髓增生异常综合征去甲基化药物临床反应的生物学标志研究进展 被引量：1

原文传递
导出
摘要 骨髓增生异常综合征(MDS)是一种起源于造血干细胞的克隆性疾病,疾病临床表现呈异质性,多数患者最终转化为急性髓细胞性白血病。近年来发现DNA甲基化异常与MDS的严重程度及预后有关,去甲基化治疗作为一种新的方法引入到MDS的治疗中。现将指导MDS患者临床合理使用去甲基化药物的生物学指标进行综述。
作者 罗朝蕊 刘霆
机构地区 四川大学华西医院血液科及血液病研究所
出处 《华西医学》 CAS 2012年第5期779-782,共4页 West China Medical Journal
关键词 骨髓增生异常综合征 去甲基化药物 治疗
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献42

  • 1Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase IU randomized study[J]. Cancer, 2006, 106(8): 1794-1803.
  • 2Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher- risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1): 52-57.
  • 3Sekeres MA, Steensma DP. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment[J]. Blood, 2009, 114(13): 2575-2580.
  • 4Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase Ⅲstudy of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study[J]. J Clin Oncol, 2011,.29(15): 1987-1996.
  • 5Silverman LR, Fenaux P, Mufti G J, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastie syndromes[J]. Cancer, 2011, 117(12): 2697-2702.
  • 6边祥海(综述),林圣云,何静松(审校).地西他滨在骨髓增生异常综合征治疗中的应用[J].国际输血及血液学杂志,2010(4):374-376. 被引量：3
  • 7邵宗鸿,张薇.骨髓增生异常综合征去甲基化治疗进展[J].临床血液学杂志,2011,24(3):259-261. 被引量：11
  • 8Jones PA, Baylin SB. The fundamental role of epigenetic events in Cancer[J]. Nat Rev Genet, 2002, 3(6): 415-428.
  • 9Quesnel B. Methylation and myelodysplastic syndromes: when and where?[J]. Leuk Res, 2006, 30(11): 1327-1329.
  • 10Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML[J]. Blood, 2009. 113(6): 1315-1325.

二级参考文献63

  • 1Iwai M, Kiyoi H, Ozeki K, et al. Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. Leukemia, 2005, 19:1367-1375.
  • 2Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002, 100:2292- 2302.
  • 3Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997, 89: 2079-2088.
  • 4Mitelman F. An Intemational System for Human Cytogenetic Nomenclature. Basel,Switzerland: S. Karger, 1995.
  • 5Cilloni D, Messa E, Messa F, et al. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes. Ann N Y Acad Sci, 2006, 1089:411-423.
  • 6Dawson DW, Hong JS, Shen RR, et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene, 2007, 26:4243-4252.
  • 7Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst, 2005,97 : 103- 115.
  • 8Brena RM, Plass C, Costello JF. Mining methylation for early detection of common cancers. Plos Med, 2006,3:2184-2185.
  • 9Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene, 2003,22:6489-6496.
  • 10Voso MT, Scardocci A, Guidi F, et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood, 2004,103:698-700.

共引文献28

同被引文献32

  • 1叶盛威,魏少忠.泛素特异性蛋白酶2与肿瘤[J].肿瘤防治研究,2014,41(5):505-508. 被引量：2
  • 2Kouzarides T. Chromatin modifications and their function[J]. Cell, 2007, 128(4): 693-705.
  • 3Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes[J]. Biochim Biophys Acta, 2004, 1695 (1/2/3): 189-207.
  • 4Suganuma T, Workman JL. Signals and combinatorial functions of histone modifications [J]. Annu Rev Bioche, 201 i, 80: 473-499.
  • 5Hake SB, Xiao A, Allis CD. Linking the epigenetic "language" of covalent histone modifications to cancer[J]. Br J Cancer, 2004, 90(4): 761-769.
  • 6Misri S, Pandita S, Kumar R, et al. Telomeres, histone code, and DNA damage response[J]. Cytogenet Genome Res, 2008, 122(3/4): 297-307.
  • 7Strahl BD, Allis CD. The language of covalent histone modification[J]. Nature, 2000, 403(6765): 41-45.
  • 8Vi]ay-Kumar S, Bugg CE, Cook WJ. Structure of ubiquitin refined at 1.8 A resolution[J], l Mol Biol, 1987, 194(3): 531-544.
  • 9Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome[J]. Semin Cell Dev Biol, 2000, 11(3): 141-148.
  • 10Oddo S. The ubiquitin-proteasome system in Alzheimer's disease[J]. J Cell Mol Med, 2008, 12(2): 363-373.

引证文献1

二级引证文献2

华西医学
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部